A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2019 Planned number of patients changed from 45 to 26.
- 25 May 2019 Status changed from suspended to recruiting.